María Elena
Díaz Rodríguez
Profesora Asociada
Hospital Universitario de Salamanca
Salamanca, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitario de Salamanca (6)
2017
-
The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma
Haematologica, Vol. 102, Núm. 12, pp. 2113-2124
2015
-
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone
Leukemia, Vol. 29, Núm. 3, pp. 705-714
2014
-
Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 Inhibition as an antimyeloma strategy
Molecular Cancer Therapeutics, Vol. 13, Núm. 2, pp. 504-516
-
Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: Implications in myeloma progression and myeloma bone disease
Oncotarget, Vol. 5, Núm. 18, pp. 8284-8305
2012
-
Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients
Leukemia, Vol. 26, Núm. 8, pp. 1862-1869
2011
-
Deficient spindle assembly checkpoint in multiple myeloma
PLoS ONE, Vol. 6, Núm. 11